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Abstract
Objective: Anticonvulsants are known to be effec-
tive to manage affective instability and aggressive
behavior by reducing neuronal excitability. This study
examined the efficacy and safety of topiramate, a novel
anticonvulsant, on disruptive behavioral problems in
children and adolescents, with or without mental retar-
dation (MR), and the differences of short-term efficacy
and safety according to the IQ levels. Methods and
Materials: Fifty-four children and adolescents with
disruptive behavioral problems were enrolled in a 6-
week, open-label study. All subjects were divided into
3 groups (subjects without MR, Non-MR; subjects with
mild MR, Mild MR; and subjects with moderate to
severe MR, Mod-Severe MR) based on their intellectu-
al ability, and treated with topiramate. Outcome mea-
sures included the Aberrant Behavior Checklist
Hyperactivity (ABC-H) and Irritability (ABC-I) sub-
scales and the Clinical Global Impression Severity
(CGI-S) scale. Results: Significant reduction of CGI-
S, ABC-H, and ABC-I scores were noted in all three
groups in the following order: Non-MR, Mild MR, and
Mod-Severe MR. Parethesia, anorexia, somnolence,
nocturnal enuresis, and urinary frequency were rela-
tively common adverse event. However, no serious
adverse events were reported. Conclusions: Topiramate
was effective and well tolerated for managing disrup-
tive behavioral problems and emotional instability in
children and adolescents.   
Key words: Topiramate, Youth, Disruptive behavior,
Mental retardation.
[Psychiatry Invest 2006; 3 (2):73-80]
Introduction
Mental retardation (MR) is associated with a higher
prevalence of psychopathology than in the general pop-
ulation, for both children and adolescents, as well as
adults. The disruptive behaviors such as aggressive
behavior toward self (self-injurious behavior including
biting, self-hitting, head banging, etc.), aggressive
behavior toward others (hitting, biting, kicking, etc.),
and generally aggressive behaviors (breaking or over-
turning furniture, breaking windows, screaming, run-
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ning, etc.) are some of the most common forms of psy-
chopathology in children and adolescents with MR.
Rutter et al. reported that the rate of behavioral prob-
lems in children with MR was several times higher
than in normal IQ children and that it is negatively cor-
related with IQ.1,2
Anticonvulsants have been used to treat affective
instability and aggressive behaviors in a variety of neu-
ropsychiatric disorders. The possible mechanisms for
the antiaggressive and mood stabilizing effect of anti-
convulsants fall into three major categories: (1) block-
ade of  voltage-gated sodium channels, (2) direct or
indirect enhancement of inhibitory GABAergic neuro-
transmission, and (3) inhibition of excitatory gluta-
matergic neurotransmission. Anticonvulsants were
effective in the amygdale-kindled rat model.3.4 In this
context, it seems that anticonvulsants can be effective
to manage affective instability and aggressive behavior
by reducing neuronal excitability. Most clinical trials
using carbamazepine and valproate in children and
adolescents demonstrated a decrease in aggressive
behavior, irritability and affective instability.5-9
Topiramate is a novel antiepileptic drug with a
proven efficacy for treating seizure disorders.10 Its
mechanisms of action include inhibition of sodium
channels blocking activity, enhancement of GABA
inhibitory neurotransmission, attenuation of excitatory
glutamatergic neurotransmission, inhibition of calcium
channels, and inhibition of carbonic anhydrase.
Topiramate has been primarily evaluated for its
potential efficacy in neurological conditions such as
migraine, neuropathic pain, essential tremor and
seizure disorder. Investigations have also begun to
evaluate the therapeutic effects of topiramate in psy-
chiatric disorders such as post-traumatic stress disor-
der,11 bulimia,12 obesity,13 bipolar disorder,14 and
schizoaffective disorder.15 A major advantage of topi-
ramate compared to other antiepileptic drugs is its
adverse events profile. Because it is free of serious
hepatotoxicity, routine blood monitoring is not neces-
sary.10 Topiramate has the advantage of often being
associated with a lack of weight gain and/or with
weight loss.16 Also, it offers the advantage of having
relatively few, drug-drug interactions.17,18
Therefore, topiramate may be potentially beneficial
in the treatment of individuals with behavioral prob-
lem, especially accompanied with MR. Janowsky et
al. conducted a retrospective study into the effects of
topiramate on aggressive, self-injurious, and disrup-
tive/destructive behaviors in the intellectually dis-
abled.19 The results suggested that topiramate might
have a role in the treatment of challenging/maladap-
tive behaviors in intellectually disabled individuals.
However, these individuals were adults having a
mood disorder. In children and adolescents with per-
vasive developmental disorder (PDD), an open-label,
retrospective study was conducted to assess the effica-
cy on associated symptoms of PDD and the tolerabili-
ty of topiramate.20 However, it remains unknown
whether topiramate is beneficial in the treatment of
disruptive behaviors in child and adolescent patients
with MR. We conducted an open-label study to evalu-
ate the efficacy and safety of topiramate on disrup-
tive/destructive behaviors in children and adolescents
with or without MR.
Methods and Materials
The subjects in the study were 54 child and adoles-
cent psychiatric outpatients (41 boys and 13 girls)
who had disruptive behavioral problems such as
aggressive-impulsive behaviors, self-injurious behav-
iors, irritability and hyperactivity. Subjects were diag-
nosed based on Diagnostic and Statistical Manual of
Mental Disorders, Fourth edition (DSM-IV)21 criteria
by two child and adolescent psychiatrists at baseline.
The DSM-IV  diagnoses of the subjects were
Attention Deficit/ Hyperactivity Disorder (38.9%),
PDD (46.3%), Tourette Disorder (11.1%), Anxiety
Disorders (7.4%), Bipolar Disorders (7.4%), etc. All
subjects were divided into 3 groups (16 subjects with-
out MR, Non-MR; 10 subjects with mild MR, Mild
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MR; and 28 subjects with moderate to severe MR,
Mod-Severe MR) based on their intellectual ability as
measured on the Wechsler Intelligence Scale. There
were no significant differences in the frequencies of
disruptive behavioral problems among the three
groups except self-injurious behavior (0.0% in Non-
MR, 30.0% in Mild MR, 67.9% in Mod-Severe MR;
p=.000) (Table 1). Among the three groups, there
were no significant differences in the frequencies of
aggressive behavior (75.0% in Non-MR, 70.0% in
Mild MR, 46.4% in Mod-Severe MR; p= .133) and
irritability (56.3% in Non-MR, 40.0% in Mild MR,
67.9% in Mod-Severe MR; p=.293)
The subjects took a tablet form of topiramate
(25mg/tablet) for the treatment of aggressive-impul-
sive behaviors, self-injurious behaviors, irritability
and hyperactivity. Topiramate was given at an initial
daily dose of 25mg, and was increased weekly in
25mg/day increments to a tolerable dose using b.i.d.
or t.i.d. regimen.
This prospective, open-label study was carried out
during 6 weeks of observation and treatment.
. The Aberrant Behavior Checklist Irritability (ABC-I)
and Hyperactivity (ABC-H) subscales and the Clinical
Global Impression Severity (CGI-S) scale were admin-
istered at baseline and at the end of the post-treatment
6th week. CGI-S is rated on a scale from 1 to 7
(1=normal, 7=extremely ill). We also investigated the
adverse events following topiramate administration in
the subjects.
Statistical analysis  
We analyzed the data at baseline using ANOVA and
chi-square test. Repeated measures ANCOVA (analysis
of co-variance) were performed to compare the CGI-S
and ABC subscales’ scores by groups and assessment
periods (pre-treatment versus post-treatment 6th week),
because the mean scores of CGI-S and ABC subscales
were significantly different (Table 2). For analysis of
TABLE 1. Comparative clinical data of the subjects
Non-MR: subjects without mental retardation; Mild MR: subjects with mild mental retardation; Mod-Severe MR: subjects with mod-
erate to severe mental retardation
N.S.: not significant statistically by chi-square test
DSM-IV Dx: diagnoses using Diagnostic and Statistical Manual of Mental Disorders, Fourth edition
ADHD: attention-deficit/hyperactivity disorder
PDD: pervasive developmental disorder 
D/O: disorder
OBS: organic brain syndrome.
Age Mean (±SD)
Male: Female ratio
IQ Mean (±SD)
DSM-IV Dx: N (%)
ADHD
PDD
Anxiety D/O
Bipolar D/O
Tourette D/O
OBS
P
Mild MR
(N=10)
Mod-Severe MR
(N=28)
Non-MR
(N=16)
Total
(N=54)
N.S.
N.S.
< .001
N.S.
.000
N.S.
.001
< .001
N.S.
10.5 (±5.6)
6:4
58.7 (±8.4)
3 (30.0%)
5 (50.0%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
2 (20.0%)
13.8 (±6.5)
23:5
37.0 (±9.8)
11 (39.3%)
19 (67.9%)
2 (7.1%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
14.9 (±6.2)
12:4
98.4 (±17.9)
7 (43.7%)
1 (6.3%)
2 (12.5%)
4 (25%)
6 (37.5%)
1 (6.3%)
14.0 (±7.8)
41:13
63.7 (±30.2)
21 (38.9%)
25 (46.3%)
4 (7.4%)
4 (7.4%)
6 (11.1%)
3 (5.5%)
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the temporal changes of CGI-S scores and reduction on
ABC subscales, we assigned the pre-treatment scores
as the covariate variable, the assessment time as the
within-subject variable, and the groups as the between-
subject variable.
Results
There were no significant differences of mean (
SD) maintenance dosage of topiramate among the
three groups (Table 2). There were significant differ-
ences of mean ( SD) body weight among the three
groups: 55.7 ( 18.8) kg in Non-MR, 31.8 ( 17.1)
kg in Mild MR, and 40.0 ( 18.0) kg in Mod-Severe
MR (F=6.009, p=.005). However, the mean mainte-
nance dosages per body weight showed no significant
differences (Table 2).
CGI-S scores were significantly changed after the
medication in all three groups (Table 3). CGI-S scores
were significantly reduced with significant interaction
TABLE 2. The mean maintenance dosage of topiramate
Non-MR: subjects without mental retardation; Mild MR: subjects with mild mental retardation; Mod-Severe MR: subjects with mod-
erate to severe mental retardation; BWt: body weight
Mean ±SD (mg/day)
Range (mg/day)
Dosage/BWt ±SD (mg/kg)
Range (mg/kg)
PMod-Severe MRMild MR Non-MR
.798
.919
F
.226
.085
100.4±87.1
12.5_400
2.4±1.3
0.42_4.88
82.5±67.7
25_200
2.4±1.3
1.14_5.00
105.0±91.7
25_400
‘
2.2±2.4
0.67_10.53
TABLE 3. Mean changes of CGI-S, ABC-H, and ABC-I scores
EMM: estimated marginal mean; CGI-S: Clinical Global Impression-severity scale (1=normal, 7=extremely ill); ABC-H: Aberrant
Behavior Checklist Hyperactivity subscale; ABC-I: Aberrant Behavior Checklist Irritability subscale; Non-MR: subjects without
mental retardation; Mild MR: subjects with mild mental retardation; Mod-Severe MR: subjects with moderate to severe mental
retardation
Note: CGI-S changes in Non-MR vs. Mild MR, p<.05 by repeated measure ANCOVA;
CGI-S changes in Mild MR vs. Mod-Severe MR, p<.01 by repeated measure ANCOVA;
ABC-H changes in Non-MR vs. Mod-Severe MR, not significant by repeated measure ANCOVA;
ABC-H changes in Mild MR vs. Mod-Severe MR, p<.05 by repeated measure ANCOVA;
ABC-I changes in Non-MR vs. Mild MR, p<.01 by repeated measure ANCOVA;
ABC-I changes in Mild MR vs. Mod-Severe MR, p<.05 by repeated measure ANCOVA.
CGI-S pretreatment
pretreatment (EMM) 
6th week (EMM)
ABC-H Pretreatment
Pretreatment(EMM)
6th week (EMM)
ABC-I pretreatment
Pretreatment (EMM)
6th week (EMM)
PMod-Severe MRMild MR Non-MR
< .001
< .001
< .001
F
54.19
113.16
199.14
6.18
5.57
4.97
32.93
29.46
26.24
26.04
19.93
18.83
5.50
5.57
4.26
28.80
29.46
24.98
19.10
19.93
15.63
4.56
5.57
3.58
23.81
29.46
21.53
9.75
19.93
12.73
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group by assessment period (F=4.70, p<.01). Through
the test of within-group assessment period effect, inter-
action group by assessment period was also significant
(F = 6.71, p < .001). Comparing assessment periods,
there was a significant difference between pre- and
post-treatment 6th week results (F=7.48, p<.01). CGI-
S scores were significantly reduced in all three groups
in the following order: Non-MR, Mild MR, and Mod-
Severe MR (Non-MR vs. Mild MR, p<.05; Mild MR
vs. Mod-severe MR, p<.01). 
There was a significant reduction of ABC-H with
significant interaction group by assessment period
(F=2.97, p<.05). In the test of within-group assessment
period effect, interaction group by assessment period
was also significant (F = 4.29, p < .01). Comparing
assessment periods, there was a significant difference
between pre-treatment and post-treatment 6th week
(F = 3.26, p < .05). ABC-H scores were significantly
reduced in all three groups in the following order (table
3): Non-MR, Mild MR, and Mod-Severe MR (Non-
MR vs. Mild-MR, p < .05; Non-MR vs. Mod-severe
MR, p<.05; Mild MR vs. Mod-Severe MR, p=.255).
ABC-I was also significantly reduced with significant
interaction group by assessment period (F=3.04,
p<.05). In the test of the within-group assessment peri-
od effect, interaction group by assessment period was
also significant (F=4.07, p< .01). Comparing assess-
ment periods, there was a significant difference between
pre-treatment and post-treatment 6th week (F = 5.74,
p<.01). ABC-I scores were significantly reduced in all
three groups in the following order (Table 3): Non-MR,
Mild MR, and Mod-Severe MR (Non-MR vs. Mild-
MR, p<.01; Mild MR vs. Mod-severe MR, p<.05). 
Table 4 shows the frequencies of topiramate-induced
adverse events. Paresthesia, anorexia, somnolence,
nocturnal enuresis, and urinary frequency were rela-
tively common in this study, but there were no signifi-
cant frequency differences among the groups except for
paresthesia. All subjects tolerated the administration of
topiramate during the study period. All adverse events
were tolerable and not serious.
Discussion
The U.S. Food and Drug Administration has approved
topiramate for use as an adjunctive therapy for partial
onset and primary generalized tonic-clonic seizures.
The recommended dosage for children with epilepsy,
aged 4-17 years, is 5-9mg/kg/day. A relatively lower
dosage of topiramate may be recommended to manage
the neuropsychiatric problems compared with epilepsy.
Hardan et al.20 reported that a mean topiramate dosage
of 3.36mg/kg/day (235mg/day) was required to treat the
behavioral symptoms in children and adolescents with
TABLE 4. Adverse reaction frequencies
Non-MR: subjects without mental retardation; Mild MR: subjects with mild mental retardation; Mod-Severe MR: subjects with
moderate to severe mental retardation:
N.S.: not significant statistically by chi-square test
Paresthesia
Anorexia
Somnolence
Urinary symptoms
: Nocturnal enuresis
: Urinary frequency
Poor concentration
P
Mild MR
(N=10) N (%)
Mod-Severe MR
(N=28) N (%)
Non-MR
(N=16) N (%)
Total
(N=54) N (%)
Adverse reaction
002
N.S.
N.S.
N.S
N.S.
N.S.
N.S.
0 (0.0%)
1 (10.0%)
1 (10.0%)
1 (10.0%)
0 (0.0%)
1 (10.0%)
1 (3.6%)
1 (3.6%)
3 (10.7%)
1 (3.6%)
3 (10.7%)
2 (7.1%)
1 (3.6%)
0 (0.0%)
6 (37.5%)
2 (12.5%)
1 (6.3%)
2 (12.5%)
1 (6.3%)
1 (6.3%)
1 (6.3%)
7 (13.0%)
6 (11.1%)
3 (5.6%)
6 (11.1%)
3 (5.6%)
3 (5.6%)
2 (3.7%)
Topiramate on disruptive behaviors in children and adolescents
78
PDD. In a few previous clinical studies, much lower
dosages of topiramate were administered to manage
migraine (mean dosage of 1.4mg/kg/day, 8.4mg/day) or
bipolar disorder (104mg/day) in children and adoles-
cents.22,23 In this study, lower dosages (2.2 to
2.4mg/kg/day, 82.5 to 105.0mg/day) of topiramate were
sufficient to improve the behavioral problems in the
subjects. Our results suggest that lower dosages of topi-
ramate might be helpful to treat neuropsychiatric symp-
toms, compared to those required for epilepsy, in chil-
dren and adolescents. 
As shown in table 3, topiramate was effective to
improve aggressive-impulsive behaviors, self-injurious
behaviors, irritability, and hyperactivity, as indicated in
the reduced CGI-S, ABC-H, and ABC-I scores in all
groups. Topiramate has been suggested to be as effec-
tive as carbamazepine and valproate in managing dis-
ruptive behaviors, and affective instability in children
and adolescents. In a pilot study8 of 10 youths with
conduct disorder, carbamazepine reduced aggressive
and explosive behaviors. However, a subsequent dou-
ble-blind study5 of carbamazepine use in 22 youths
with conduct disorder failed to show the superiority of
carbamazepine over a placebo in reducing aggressive
behavior. A brief report of a double-blind, placebo-
controlled, crossover study6 of valproate demonstrated
a decrease in explosive temper and mood lability in
children and adolescents with oppositional defiant dis-
order and conduct disorder. Valproate has been report-
ed to be also effective in controlling disruptive behav-
iors in children and adolescents with MR or autism
spectrum disorder. In two open trials,7,9 valproate
showed efficacy of 71-78% in reducing affective insta-
bility, impulsivity, aggressive behavior, irritability, and
self-injurious behavior.
In the Expert Consensus Survey,24 anticonvulsants
were generally recommended for managing self-injuri-
ous behavior, physical aggression, agitation, hyperac-
tivity, anxiety, and suicidal ideation/behavior in sub-
jects with MR. Anticonvulsants were highly recom-
mended for treating severe and persistent hyperactivity
in MR patients, whose symptom severity of hyperactiv-
ity did not meet the full criteria of ADHD.
Topiramate is known to be effective in treating affec-
tive instability, irritability, and aggressive behavior, at
least as an adjunctive mood stabilizer. Only in Non-
MR of our study (see table 1), four of sixteen subjects
were comorbid with bipolar disorder, which may have
influenced the topiramate effect on affective instability,
irritability, and aggressive behavior as a confounding
factor. We performed repeated measure ANCOVA for
all groups, excluding the four subjects with bipolar dis-
order from Non-MR. Nevertheless, the comorbidity of
bipolar disorder did not influence the ANCOVA results
in terms of the significant reduction of CGI-S and ABC
scores in the group by assessment period, comparison
between pre-treatment and post-treatment 6th week, and
comparisons of treatment periods in Non-MR vs. Mild
MR and Mild MR vs. Mod-Severe MR.
Compared to the pre-treatment period, CGI-S and
ABC scores improved significantly at post-treatment
6th week period in all three groups. The treatment effi-
cacy of topiramate on disruptive/destructive behavior
was noted at post-treatment 3 months and 25 ( 16)
weeks in two retrospective studies19,20 in adults with
MR, and children and adolescents with PDD. Our
prospective design revealed the short-term effects (6
weeks) of topiramate in decreasing the severity of dis-
ruptive behaviors in children and adolescents with or
without MR. We defined 'responder' as cases with 'very
much improved' and 'much improved'. The overall
responder rate was 53.7%, but the rate declined from
93.8% in Non-MR, to 60% in Mild MR, and 28.8% in
Mod-Severe MR. This suggests that topiramate showed
more favorable efficacy on disruptive behaviors in
patients with higher cognitive functions. 
It has been reported that the most common adverse
events of topiramate are central nervous system
(CNS)-related adverse events and paresthesia. In
CNS-related adverse events of our study, anorexia
(11.1%) and somnolence (5.6%) were relatively com-
mon, followed by poor concentration (3.7%). There
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were no reports of other CNS adverse events such as
dizziness, fatigue, confusion, and abnormal vision.
This study showed lower frequencies of CNS adverse
events than previous reports of topiramate tolerability,
such as 12.9~16.8% for anorexia, 16.1~21.1% for
somnolence, and 12.6~19.4% for impaired concentra-
tion as reported by Biton et al.17 This discrepancy of
the frequencies could be related with topiramate
dosage. The mean doses of our study were lower
(range 82.5-105.0mg/day) than the 346 to 353mg/day
in Biton et al.’s report.17 It has been generally accepted
that CNS adverse events are minimized by lowering
doses followed by slow titration.18,25
The most common adverse event in our study was
paresthesia, which is known to be related to the inhibi-
tion of carbonic anhydrase activity by topiramate.26
The prevalence of paresthesia was relatively lower in
the two MR groups (Mild MR and Mod-Severe MR)
than in Non-MR. In MR subjects, the limited ability to
express the subjective sense may lower the reports of
paresthesic sensation. Antonio et al. reported only
observable adverse events in their study, although
paresthesia was one of the common adverse events in
other previous studies.20
In our results, urinary adverse events such as noctur-
nal enuresis and urinary frequencies were also com-
mon, being reported by 11.1% (6 of 54) of the subjects.
Urinary symptoms have only been rarely reported in
previous studies for topiramate. It is unclear whether
the urinary symptoms observed in the present study
were associated with topiramate administration.
This study had two potential limitations. First, the
trial was open label without a placebo-control. The sec-
ond limitation was the presence of comorbid psychi-
atric disorder and different rates of comorbidities
between the groups.
Conclusions
Topiramate was effective and well tolerated in the
management of disruptive/destructive behaviors and
affective instability in child and adolescent patients. In
future research, systematically designed clinical studies
will be required to evaluate the efficacies on stabilizing
behavior and mood problems, and the safety of topira-
mate in children and adolescents with mental disorders. 
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